Show Notes
Editor’s note: At the time of recording, Alan Bash was serving as Interim CEO of Legend Biotech. He has since resumed his role as President of CARVYKTI® following the appointment of Ingrid Zhang as CEO.
In this episode of The BioHub by Avetix, I’m joined by Alan Bash, President of CARVYKTI® at Legend Biotech.
Alan shares what drew him to Legend, what he believes has made the company such a standout success in cell therapy, and his experience stepping into the Interim CEO role during an important period of transition.
We also discuss the journey behind CARVYKTI, the importance of global partnerships, the challenges of manufacturing and scaling cell therapy, and what the next chapter could look like for Legend as it builds beyond its first major commercial success.
More from The BioHub - by Avetix
In this episode of The BioHub, Amber is joined by Dr. Garry Pairaudeau, Co-Founder and CEO, and Dr. Anthony Bradley, Co-Founder and CSO of Dalton Tx. Having previously worked together at Exscientia, Garry and Anthony went on to co-found Dalton Tx. bringing together AI, scientific expertise and software engineering to help accelerate drug discovery. We explore their journey the challenges of translating advances in AI into meaningful scientific impact, and the importance of separating genuine innovation from industry hype. We also discuss the evolving role of AI in drug discovery, building a science-driven company, and what the future could hold for AI-enabled therapeutics.
Why spend months recreating research tools that another lab has already built? In this episode of The BioHub, we’re joined by Greg Crescenzi from Addgene to discuss how sharing scientific materials can reduce duplicated work, save researchers time and help biotech discoveries move faster. From plasmids and CRISPR tools to viral vectors and antibodies, Greg explains how Addgene helps scientists build on existing research—and why improving access between academia and industry is the next challenge. We cover: • The frustration that sparked Addgene’s founding • How sharing research tools helped CRISPR reach thousands of organisations • The barriers between academic research and commercial biotech • Partnerships supporting better sequencing and new research tools • Why unsuccessful experiments contain information worth sharing • Where AI and Addgene’s research data could create new opportunities Subscribe to The BioHub for more conversations with the people advancing biotech. #Biotech #Addgene #CRISPR #BioHub
In this episode of The BioHub by Avetix, I’m joined by Marshall Fordyce, Founder and CEO of Vera Therapeutics.
In this episode of The BioHub, Amber is joined by Dr. Chris Moxham, Co-founder and CEO of Transcripta Bio, and Clayton Mellina, CTO, to explore how transcriptomics and AI are opening up new possibilities in drug discovery. Chris and Clayton explain how Transcripta connects the changes disease causes in cells with the effects of potential treatments. They discuss combining phenotypic screening with target-based discovery, finding new uses for existing medicines, and reducing risk earlier in development. The conversation covers their work in genetically defined autism spectrum disorders and Huntington’s disease, their collaboration with Mayo Clinic, and how AI agents could help small scientific teams explore thousands of hypotheses.
In this episode of The BioHub Podcast by Avetix, we welcome Neil Warma, President and CEO of ProMIS Neurosciences, a clinical-stage biotechnology company developing next-generation therapies targeting toxic, misfolded proteins associated with neurodegenerative diseases. Neil shares insights from his extensive career building and leading biotechnology companies, before exploring ProMIS' differentiated approach to treating Alzheimer's disease. We discuss PMN310, an antibody designed to selectively target toxic amyloid-beta oligomers while avoiding plaque, its ongoing Phase 1b PRECISE-AD clinical trial, and the potential to improve both efficacy and safety in Alzheimer's treatment. The conversation also explores ProMIS' broader ambitions across ALS and Parkinson's disease, upcoming clinical milestones, and Neil's perspective on leadership, financing, and building successful biotechnology companies.